NEO vs SLNO vs JPM vs BAC vs RARE

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -0. 5% for Bank of America Corporation (BAC). Bank of America Corporation (BAC) offers the better valuation at 14. 7x trailing P/E (12. 6x forward), making it the more compelling value choice. Analysts rate NeoGenomics, Inc. (NEO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.

7x versus Soleno Therapeutics, Inc. at 135. 9x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Bank of America Corporation's 0. 82x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -76. 3% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: JPM returned +465. 8% versus SLNO's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bank of America Corporation (BAC) is the lower-risk stock at 0.

86β versus Ultragenyx Pharmaceutical Inc. 's 1. 43β — meaning RARE is approximately 66% more volatile than BAC relative to the S&P 500. On balance sheet safety, Soleno Therapeutics, Inc. (SLNO) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus -0. 5% for Bank of America Corporation (BAC). On earnings-per-share growth, the picture is similar: Soleno Therapeutics, Inc. grew EPS 108. 9% year-over-year, compared to -35. 5% for NeoGenomics, Inc.. Over a 3-year CAGR, RARE leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -79. 5% for RARE. At the gross margin level — before operating expenses — SLNO leads at 98. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Bank of America Corporation's 0. 82x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 6x forward P/E versus 61. 9x for NeoGenomics, Inc. — 49. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 98. 6% to $48. 36.

In this comparison, BAC (2.

3% yield), JPM (1. 9% yield) pay a dividend. NEO, SLNO, RARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bank of America Corporation (BAC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

86), 2. 3% yield, +368. 2% 10Y return). Both have compounded well over 10 years (BAC: +368. 2%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NEO (Healthcare) and SLNO (Healthcare) and JPM (Financial Services) and BAC (Financial Services) and RARE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NEO is a small-cap quality compounder stock; SLNO is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; BAC is a large-cap deep-value stock; RARE is a small-cap high-growth stock. JPM, BAC pay a dividend while NEO, SLNO, RARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.